This TKi was approved for solid, and metastatic HER2-positive breast tumors [36,37] preventing the phosphorylation of HER1 (T1173) and HER2 (T1221/1222), markers of poor prognosis in breast cancer patients [15,23]. Here, ERBB2 is linked to breast carcinoma.